Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Data Backup and Recovery

Data Backup and Recovery

View Detailed Analysis

Analytics Overview

6
Form 483s Issued
0
483s converted to WL
6
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
29 Feb 2024
Eugia SEZ Private Limited
Drugs
09 Nov 2023
Shilpa Medicare Limited
Drugs
19 May 2023
FUJINOMIYA FACTORY OF TERUMO CORP
Drugs
30 Mar 2023
TERUMO YAMAGUCHI CORPORATION
Drugs
10 Feb 2023
AGC Biologics Inc.
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Marcellinus D Dordunoo
2
0
Brandon L Mariner
1
0
Brian Janelsins, PhD
1
0
Charles Yuan-Chia Kuo, PhD
1
0
Ashar P Parikh
1
0
TITLE/ COMPANY Issue Date Status Details
Failure to maintain a backup file of data entered into the computer or related system
Eugia SEZ Private Limited
29 Feb 2024 Normal Justification: The observation directly mentions a failure to maintain backup files for critical data, specifically noting that current practices lack function to save data internally or via backup.
Excerpt: Failure to maintain a backup file of data entered into the computer or related system.
View Details
You failed to maintain a backup file of data entered into the computer or related system.
Shilpa Medicare Limited
09 Nov 2023 Normal Justification: The issue stems from a failure to properly execute and ensure robust data backup and recovery processes, leading to significant data loss.
Excerpt: "Your procedure, SMLJ/ITD/SOP-GEN/002-01 Back up, Restore, Verification and Archival of Electronic Data ... does not ensure that the complete data from your standalone laboratory equipment are backed up securely."
View Details
Failure to maintain a backup file of data entered into the computer or related system.
FUJINOMIYA FACTORY OF TERUMO CORP
19 May 2023 Normal Justification: Backup and recovery processes are directly related to ensuring data availability and integrity.
Excerpt: Data from the (b) (4) (b) (4) utilized in testing of product prepared in (b) (4) (b) (4) and (b) (4) located in the (b) (4) are not backed up.
View Details
Backup data is not assured as complete and secure
TERUMO YAMAGUCHI CORPORATION
30 Mar 2023 Normal Justification: The observation explicitly identifies issues related to backup data integrity and protection during power disruptions.
Excerpt: Backup data is not assured as complete and secure from alteration, erasure or loss...
View Details
Your firm has not established adequate procedural controls to protect the electronic data acquisition and manufacturing control systems used for DS manufacturing in Building at the AGC Biologics Bothell facility.
AGC Biologics Inc.
10 Feb 2023 Normal Justification: Validating backup and recovery processes ensures data remains accessible and intact after any disruption.
Excerpt: Audit trails enabled in the data acquisition system are not reviewed for each data set during the lot review process.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.